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Abstract 
Background: Changes to the epigenome with aging, and DNA modifications in particular, have been proposed as a 
central regulator of the aging process, a predictor of mortality, and a contributor to the pathogenesis of age-related 
diseases. In the central nervous system, control of learning and memory, neurogenesis, and plasticity require changes 
in cytosine methylation and hydroxymethylation. Although genome-wide decreases in methylation with aging are 
often reported as scientific dogma, primary research reports describe decreases, increases, or lack of change in meth-
ylation and hydroxymethylation and their principle regulators, DNA methyltransferases and ten-eleven translocation 
dioxygenases in the hippocampus. Furthermore, existing data are limited to only male animals.
Results: Through examination of the hippocampus in young, adult, and old male and female mice by antibody-
based, pyrosequencing, and whole-genome oxidative bisulfite sequencing methods, we provide compelling evi-
dence that contradicts the genomic hypomethylation theory of aging. We also demonstrate that expression of DNA 
methyltransferases and ten-eleven translocation dioxygenases is not differentially regulated with aging or between 
the sexes, including the proposed cognitive aging regulator DNMT3a2. Using oxidative bisulfite sequencing that 
discriminates methylation from hydroxymethylation and by cytosine (CG and non-CG) context, we observe sex differ-
ences in average CG methylation and hydroxymethylation of the X chromosome, and small age-related differences in 
hydroxymethylation of CG island shores and shelves, and methylation of promoter regions.
Conclusion: These findings clarify a long-standing misconception of the epigenomic response to aging and demon-
strate the need for studies of base-specific methylation and hydroxymethylation with aging in both sexes.
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Background
Epigenetic control of the genome through DNA and his-
tone modifications is potentially a critical regulator of 
the aging process [1]. For DNA methylation in particular, 
recent studies have revealed the possibility of an aging 
“clock” in the form of DNA methylation that indicates 
chronological age [2, 3]. DNA methylation changes with 
aging may even be predictive of mortality [4]. In the 
nervous system, DNA methylation [5] and hydroxymeth-
ylation [6] have emerged as critical processes in memory 
formation [7] that may be disrupted with aging, leading 
to cognitive decline [8, 9]. Altered epigenome regulation 
is also potentially a contributor to age-related neurode-
generation including Alzheimer’s disease [10]. From a 
geroscience perspective [11], it is essential that we clar-
ify and expand our understanding of aging-associated 
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alterations of epigenetic processes in the brain to deter-
mine their contribution to health and disease.
DNA methylation (mC) and hydroxymethylation 
(hmC) occur at the 5 position of the pyrimidine ring of 
cytosines, and while predominantly occurring in CG 
dinucleotide contexts, it is also found in CH (H being 
C, A, or T) contexts [12]. DNA methyltransferases 
(DNMTs) maintain methylation patterns during cell 
division (DNMT1) and add de novo mC (DNMT3a and 
DNMT3b) in response to stimuli [13]. Tet methylcyto-
sine dioxygenases (TETs) oxidize mC into hmC, as well as 
the rarer formylcytosine (fC) and carboxylcytosine (caC) 
[14]. Several hypotheses regarding DNA methylation 
with brain aging have been proposed. These include (1) 
genomic hypomethylation, a genome-wide decrease in 
methylation levels across the genome [15]; (2) regulated 
changes, both hypomethylation and hypermethylation, 
at specific genomic locations, that are unique to individ-
ual cells and organs [16]; (3) an aging clock of regulated 
changes in methylation at common locations across tis-
sues/cells and even species [3]; and (4) epigenetic drift 
where DNA methylation patterns become disordered and 
diverge with time [17].
It is often stated that there is less global genomic meth-
ylation (hypomethylation) with aging as a consequence of 
decreased DNMT expression, and this is often presented 
as dogma in review articles [15, 18–20]. However, exami-
nation of the primary literature regarding hippocam-
pal aging presents contradictory evidence for both mC 
levels [21–25] (Additional file  1: Table S1) and DNMT 
expression [8, 21, 25–27] (Additional file 1: Table S2). In 
studies of wild-type rodent laboratory models and aging 
time points that meet well-established definitions [28], 
increased, decreased, and no change in total mC and 
DNMT expression have been reported. DNMT3b is an 
exception with no reports of changes in expression with 
aging. The discordance in the literature is not obviously 
attributable to the models used (e.g., by mouse strain) or 
the endpoints assessed (e.g., mRNA vs protein). Reports 
on hmC (Additional file  1: Table S3) and its regulating 
TET genes (Additional file  1: Table S4) are less numer-
ous, but also do not present a clear understanding of 
their regulation with aging [22, 29–31]. A notable omis-
sion evident in this literature is the absence of studies 
in female animal models. Given the profound sex dif-
ferences in brain aging [32–35], sex-specific regulation 
of DNA methylation (e.g., X-inactivation [36]), and the 
laudable recognition that both sexes need to be analyzed 
separately in preclinical research [37], studies examining 
both sexes with aging are clearly warranted.
To address this fundamental lack of clarity in the lit-
erature, genomic mC and hmC and the expression of 
the genes responsible for these modifications, DNMTs 
and TETs, respectively, were assessed in the hippocam-
pus of young (3  months), adult (12  months) and old 
(24 months) male and female C57Bl6 mice using a vari-
ety of analytical methods. Our results demonstrate: (1) 
absence of a change in total genomic levels of 5mC or 
5hmC and expression of DNMTs and TETs with aging 
and (2) DNMT3a2, a proposed regulator of age-related 
cognitive decline [8], not expressed at physiologically rel-
evant levels after early development. These data resolve 
several critical controversies of epigenetic changes with 
brain aging. We find that sex- and age-related differences 
in average mC and hmC occur within specific cytosine 
contexts (CG/CH), X chromosome, and genomic ele-
ments such CG island (CGI) shores and shelves, and 
in promoter regions. These findings demonstrate the 
need for studies examining age-related mC and hmC 
changes in a base- and strand-specific manner across the 
genome in both sexes to identify specific regions of dif-
ferential modification with aging. Future studies of spe-
cific, isolated cell types are also needed to extend these 
findings. The study also demonstrates the limitations of 
many commonly used epigenomic methods and pro-
vides approaches for quantitatively rigorous epigenomic 
studies through replication and inclusion of quantitative 
controls.
Results
Two independent cohorts of young (3 M), adult (12 M), 
and old (24 M) male and female C57Bl6 mice were gen-
erated for these studies (Fig.  1). Mice were purchased 
from the NIA Aging Rodent Colony and housed at two 
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Fig. 1 Experimental design. Design of the study including animal 
groups, assays performed, and sample sizes for each assay. For both 
sets of mice, total sample size was n = 8–10/sex–age
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acclimate. Female mice were monitored for estrous 
cycle stage by vaginal lavage and microscopy. At tis-
sue collection weight were 3  M male (27.7  ±  1.5), 
3 M female (21.7 ±  1.1), 12 M male (30.8 ±  1.7), 12 M 
female (24.1 ± 1.4), 24 M male (32.1 ± 1.9), 24 M female 
(27.2 ± 1.5). Mice were euthanized and hippocampi dis-
sected and flash frozen, with all females being in diestrus 
at the time of tissue collection. Both sets of animals were 
used for the gene expression studies. mC ELISA analysis 
was also performed on both cohorts. After exhaustion 
of the DNA samples in Set 1 (much of the sample being 
used in other studies), the remainder of the DNA analy-
ses (pyrosequencing, hmC ELISA, and oxidative bisulfite 
sequencing) were performed on Set 2.
DNMT expression and aging
To first examine mRNA expression of DNMTs, qPCR was 
performed on both mouse cohorts. DNMT1, DNMT3a 
and DNMT3b were examined (Fig.  2). For DNMT3a, 
three independent assays were used, as DNMT3a is 
expressed as both a long (DNMT3a1) and short form 
(DNMT3a2) across mammalian species [38]. Assays 
were designed to detect a common region of DNMT3a1 
and DNMT3a2 (DNMT3a), as well as isoform-specific 
regions of DNMT3a1 or DNMT3a2. No consistent age-
related changes [two-way ANOVA with sex and age as 
factors and Benjamini–Hochberg multiple testing correc-
tion (BHMTC) for the number of genes examined] across 
the two cohorts in any of the DNMT mRNAs examined 
were evident, regardless of whether the analysis com-
bined both sexes or was analyzed in a sex-specific manner 
(Fig. 2). No sex differences were observed in expression 
of any of the mRNAs. DNMT3a2 was not detected in the 
qPCR experiments in either animal cohort.
DNMT3a2 developmental expression and with aging
The lack of DNMT3a2 expression was unexpected con-
sidering the assay used (Assay #1, Additional file 1: Table 
S5) is identical to the one used in a previous report that 
describes a decline in expression in the mature hip-
pocampus with aging [8]. DNMT3a2 is a truncated form 
of DNMT3a found across mammals that utilizes an alter-
nate transcription start site [38, 39]. While DNMT3a2 
does not have any unique protein-coding sequence, it has 
an alternate 5′ UTR which allows specific detection of 
this mRNA. To further examine DNMT3a2, we designed 
a second assay (Assay #2) shifted slightly from the loca-
tion of the primers and probe for Assay #1 to specifically 
detect DNMT3a2 (Fig.  3a). No DNMT3a2 expression 
was reliably observed by qPCR in either Set 1 or Set 2 
mice with Assay #2 as well. To ensure that both assays 
were amplifying the appropriate sequence, amplicons 
were generated from embryonic brain (E11) RNA, which 
contains high levels of DNMT3a2 [40]. Amplicons were 
examined by electrophoresis and Sanger sequencing, 
and both assays were found to produce only the desired 
amplicon of the appropriate sequence (data not shown).
While these data suggest that DMNT3a2 is not 
expressed in the adult hippocampus, it could be that the 
qPCR approach is not sufficiently sensitive to detect very 
low levels of DNMT3a2 expression. To increase sensitiv-
ity, both assays were used in a chip-based digital PCR 
format which contains 20,000 individual wells to abso-
lutely quantify/count the number of transcript copies in 
embryonic brain (E11 and E18), postnatal brain (PN1), 
and mature hippocampus (3  M) without the need for 
endogenous qPCR controls that often change in expres-
sion over development. DNMT3a2 has been reported 
to be highly expressed during early development in the 
CNS and then declines over time with no expression 
evident in adults [40, 41]. DNMT3a2 transcript levels 
were highest at E11, decreasing by an order of magni-
tude at each step to E18, PN1, and mature hippocampus 
(3  M) as measured by both assays (Fig.  3b). Expression 
levels were at the limit of detection for the mature hip-
pocampus (~200 copies/µg RNA), with background lev-
els, as determined by no reverse transcription controls, 
being ~15 copies/µg RNA. For comparison, levels of 
DNMT3a1 were examined in E18 brain and mature hip-
pocampus. At E18, brain DNMT3a1 levels were tenfold 
higher than DNMT3a2, and in mature mice, hippocam-
pal DNMT3a1 levels were nearly 1000-fold higher than 
DNMT3a2. To address the possibility that the previously 
reported changes in DNMT3a2 expression with aging are 
in these near background levels of expression, the dPCR 
approach was applied to young and old male and female 
mouse hippocampal samples. No difference in these very 
low levels (~200 copies/ug of RNA) of DNMT3a2 was 
observed (Fig. 3c).
Previous reports have described an induction of 
DNMT3a2 expression with bicuculline or KCl treatment 
in embryonic hippocampal cultures [8], and replication 
of these findings was also attempted as a positive control. 
Repeating these experiments, inductions in DNMT3a2 
expression, but to a smaller extent than previously 
reported, were evident in cultures (Fig.  3d). Seeking to 
identify a potential source of the differences between the 
findings of this study and previous reports, the amplifi-
cation efficiency of the DNMT3a2 assays was examined. 
Efficiencies were found to be 76 % for Assay #1 and 75 % 
for Assay #2 (Fig.  3e). Previous quantitation assumed 
100  % amplification efficiency (calculating group differ-
ences as 2Ct instead of 1.75Ct) and would therefore 
overestimate differences between groups. This potentially 
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provides a reason that no changes were observed with 
aging and the inductions with bicuculline and KCl were 
not as large.
Though previous reports [8] examining DNMT3a2 
expression with aging did not find protein expression in 
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Fig. 2 Gene expression analysis of DNMTs. mRNA levels of DNMTs were assessed by qPCR in hippocampi of both sets of mice. Data were analyzed 
both with sexes combined (one-way ANOVA on age) and with sexes analyzed independently (two-way ANOVA on age and sex). No consistent 
changes were evident in a DNMT1, b pan-DNMT3a (combination of long, a1, and short, a2, isoforms), c DNMT3a1, or e DNMT3b. d DNMT3a2 was 
not detectable. Data are scaled to zero for the young group in the combined sexes analysis and to young female for the sex separated analysis 
with the y-axis scale presented as % change from zero. Boxes encompass the 25th to 75th percentile with bars indicating 10th and 90th percentiles. 
Median lines are indicated in the boxes
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DNMT3a2 expression could be much higher at the pro-
tein than mRNA level. Given that the literature reports 
many different molecular weights for DNMT3a1 and 
DNMT3a2 [38, 42, 43] and the high levels of homology 
with DNMT3b, a set of polyclonal and monoclonal anti-
bodies against the DNMT3a1-specific N-terminus and 
DNMT3a1/DNMT3a2 common C-terminus (Fig.  4a) 
including those in previous reports [8, 38, 44] were used 
Ct










































































































Fig. 3 DNMT3a2 mRNA expression. Four independent sets of gene expression assays were used in these studies to specifically examine (a) long 
(DNMT3a1), short (DNMT3a2), or both isoforms. DNMT3a2 copy number, expressed as copy number per microgram of RNA, was analyzed (b) in E11, 
E18, and PN1 brain and in mature (3 M) hippocampus (HP). Expression declined from a peak level at E11 to a low at 3 M that was slightly higher than 
background levels (No RT). DNMT3a1 copy number was analyzed for comparison in E18 brain and 3 M old hippocampus. c DNMT3a2 copy number 
was analyzed with Assay #1 in hippocampi from young and old, male and female Set 2 mice (n = 4/group). d Induction of DNMT3a2 by KCl, and to 
a lesser extent bicuculline in hippocampal embryonic cultures was determined by qPCR. e Amplification efficiency of both DNMT3a2 assays was 
derived from a dilution series of input cDNA and in both cases was found to be 75 %
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to detect DNMT3a. First a FLAG-tagged DNMT3a1 was 
overexpressed in HEK cells to provide a positive con-
trol (Fig.  4b). DNMT3a1-FLAG was affinity purified, 
and purified protein was probed with all four primary 
antibodies (Fig.  4c) giving a single band at ~140  kDa 
providing evidence that all four antibodies can detect 
DNMT3a1. Protein lysates from E11, E18, and PN1 brain 
and 3  M hippocampus were probed with all four anti-
bodies. DNMT3a1 was initially detected in E11, E18 and 
PN1 samples, but not in mature hippocampus (data not 
shown). Samples were rerun with twice the protein load 
(30  μg) for the hippocampus as the E11, E18, and PN1 
brain (15  μg) (Fig.  4d). The full-length DNMT3a1 was 
detected in all samples, though at a lower level in the 
hippocampus even given the high protein loading. To 
identify DNMT3a2, banding was examined for species 
present in the C-terminal antibodies, but not present in 
the N-terminal antibodies. DNMT3a2 is predicted to be 
~24  kDa smaller than DNMT3a1. While a major band 
was evident at ~95  kDa, this was also evident in N-ter-
minal, DNMT3a1-specific antibodies. Some very minor 
bands were present, but there was no unambiguous 
identification of DNMT3a2 in any of the samples. While 
these findings do not obviate the potential for DMNT3a2 
protein to be expressed in these samples, the lack of any 
previous reports definitively demonstrating endogenous 
DNMT3a2 protein expression in the CNS and the much 
lower gene expression of DNMT3a2 as compared to 
DMNT3a1 (above) suggests that DNMT3a1 is the pre-
dominant protein form of DNMT3a expressed in the 
CNS. As previous reports examining DMNT3a2 report 
many immunoreactive bands [8, 38] and the high levels 
of C-terminal homology with DNMT3b isoforms [38], 
development and validation of affinity reagents for detec-
tion of DNMT3a2 are needed to definitively answer the 
question of DNMT3a2 protein expression with aging in 
the CNS.
TET expression across sexes and ages
For completeness, the expression of TET1, TET2, and 
TET3 was examined in both cohorts of mice. No consist-
ent age- or sex-related changes (two-way ANOVA on sex 
and age with BHMTC) in the hippocampal expression of 
any of the TET genes were observed (Fig. 5).
Meta‑analysis of public data for DNMT and TET expression
Utilizing public human gene expression data from the 
NCBI Gene Expression Omnibus for which age and tis-
sue data could be extracted, a linear mixed-effects model 
was constructed to estimate DNMT and TET expression 
with age. Analyzing the general signature of aging across 
all available tissues for 16,044 samples suggested no evi-
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Fig. 4 DNMT3a2 protein expression. a Four different antibodies 
were used in these experiments, two with antigens in the DNMT3a1-
specific N-terminal region and two with antigens in the DNMT3a1/
DNMT3a2 common C-terminal region. b As a positive control and to 
provide a reference molecular weight, the full-length human DNMT3a 
protein with a FLAG tag was overexpressed in HEK cells. Cell lysates 
with the overexpression vector and empty vector were probed with 
anti-FLAG antibody. DNMT3a was detected at ~140 kDa (arrow), but a 
non-specific band at ~75 kDa was also detected. Therefore, the FLAG-
tagged DNMT3a was affinity purified on an anti-FLAG column. c The 
purified protein (0.1 μg) was probed with all four primary antibodies, 
returning a single band at ~140 kDa (arrows) demonstrating that all 
four antibodies could detect DNMT3a at the correct molecular size 
for future experiments. d Protein lysates from E11, E18, PN1 brain and 
3 M hippocampus (15 μg) were probed with all four primary antibod-
ies. The full-length DNMT3a was detected with all antibodies though 
with very weak signal in 3 M hippocampal samples (data not shown). 
To increase the likelihood of detecting DNMT3a in the hippocampal 
sample, immunoblots were performed again but with twice the 
protein loading in hippocampal samples (30 μg) as the other samples 
(15 μg). Full-length DNMT3a was detected including in hippocampal 
samples (arrows)—though the signal was very low for SC-36769 and 
64B1446 antibodies. As the C-terminal antibodies should also detect 
the shorter form of DNMT3a, DNMT3a2, the PA511141 and 64B1446 
blots were examined for banding not found with the N-terminal anti-
bodies. While a ~95-kDa band was observed, it was also evident with 
the N-terminal antibodies (open circles). No unambiguous banding 
was evident that could be attributed to DNMT3a2
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file  1: Table S7). Analysis of 496 samples annotated as 
“brain” (including specific substructures) (Table 1) simi-
larly showed no significant changes in expression with 
age.
Methylcytosine (mC) levels with aging and between sexes
As the primary literature includes a number of contra-
dictory findings regarding total hippocampal mC levels 
(Additional file 1: Table S1) with aging and no previous 
reports have examined female mice, total levels of mC 
were first analyzed by ELISA. ELISA-based approaches 
are specific to mC; however, they do not differentiate 
between CG and CH contexts or provide chromosomal 
or other locational information on where mC residues 
are located. Historically, mCG levels have been a focus of 
attention, but recent findings have conclusively demon-
strated non-CG methylation (mCH) is abundant, espe-
cially in the CNS [41, 45], and serves a functional role 
in genomic regulation [46, 47]. No age-related changes 
were observed (Fig. 6a) in mC, but there was a sex effect 
(p  =  0.002 two-way ANOVA, n  =  4/group) that was 
evident in pairwise post hoc comparisons [Student–
Newman–Keuls (SNK)] for adult (p  =  0.014) and aged 
(p  =  0.038) mice with higher levels in males. Of note 
was that the observed mC levels of ~10  % were lower 
than those reported in some ELISA studies [24, 25] and 
from deep sequencing [41, 45]. The standard curve used 
with most ELISAs is generated from a small in  vitro 
methylated sequence (mCG only). This sequence has 
five times the density of CG sites as the mouse genome 
and therefore likely underestimated the absolute lev-
els in these mouse samples. To more accurately quan-
tify whole-genome levels, mouse methylation standards 
were generated in which mouse genomic DNA was 
methylated in vitro by M. SssI to produce a high stand-
ard (~95  % mCG) or whole genome amplified in the 
absence of methyltransferases to produce a low methyla-
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Fig. 5 Gene expression analysis of TETs. mRNA levels of TETs were assessed by qPCR in hippocampi of both, sets of mice. Data were analyzed both 
with sexes combined (One-way ANOVA on age) and with sexes analyzed independently (two-way ANOVA on age and sex). No consistent changes 
were evident in a TET1, b TET2, or c TET3. Data are scaled to zero for the young group in the combined sexes analysis and to young female for the 
sex separated analysis with the y-axis scale presented as % change from zero. Boxes encompass the 25th to 75th percentile with bars indicating 10th 
and 90th percentiles. Median lines are indicated in the boxes
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Table 1 Meta-analysis of age-related DNMT and TET expression in brain
To test whether the expression levels of these genes change with age, we used a linear mixed-effects (lme4) model: [GeneExpression ~ Age: 
TissueID + (1|ExperimentID) + (1|PlatformID)]. Shown above is the age–tissue interaction term for brain. “Coef” describes the estimated coefficient of the change in 
Z-score per year for the expression of each gene, the standard error (SE), and t-statistic for the analysis. The p value shows that none of the estimated gene expression 
changes with age are statistically significant
Entrez ID Symbol Chr Name Coeff. SE t p value
80312 TET1 10 Tet methylcytosine dioxygenase 1 −0.00192 0.006 −0.34 0.73
54790 TET2 4 Tet methylcytosine dioxygenase 2 −0.00002 0.005 −0.004 1.0
200424 TET3 2 Tet methylcytosine dioxygenase 3 −0.00033 0.005 −0.064 0.95
1786 DNMT1 19 DNA (cytosine-5-)-methyltransferase 1 0.00784 0.007 1.093 0.27
1788 DNMT3a 2 DNA (cytosine-5-)-methyltransferase 3 alpha 0.004 0.004 0.980 0.33
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Fig. 6 Global mC levels: ELISA and pyrosequencing. a Total/global levels of hippocampal mC were analyzed by ELISA with synthetic methylation 
standards (young, adult, and old, females and males Set 1). (*p < 0.05 Student–Newman–Keuls pairwise post hoc test following two-way ANOVA). 
b Using a mouse whole-genome methylation standard curve, the Set 2 samples (young and old, females and males) were analyzed by mC ELISA. 
Repeat element methylation was analyzed by pyrosequencing of the c B1 element and the d LINE1 repeat (young and old, females and males Set 
2). No differences were evident in any of the individual CG sites or in the mean of the element
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were verified by pyrosequencing. The ELISA was then 
repeated with these standards, and DNA from only 
young and old Set 2 mice was analyzed to increase sam-
ple size (n =  6/group). With the appropriate standards, 
the absolute levels of mC were similar to those reported 
in sequencing studies. Again, no age effect was observed, 
and a marginally higher level of total mC was evident in 
males versus females (p  <  0.05, factor of sex, two-way 
ANOVA) (Fig. 6b). However, no significant pairwise post 
hoc differences (SNK) were observed.
A proposed surrogate endpoint for total methylation 
levels is to examine repeat element methylation levels by 
pyrosequencing [48, 49]. This has the advantage of spe-
cifically examining repeat elements such as long inter-
spersed repeat elements (LINEs) and short interspersed 
repeat elements (SINEs), which account for 19 and 8  % 
of the genome, respectively [50], with the caveats that 
bisulfite conversion cannot distinguish between mC and 
hmC. The SINE element B1 (Fig.  6c) and the LINE ele-
ment LINE1 (Fig. 6d) were examined both at the individ-
ual CG site level and by combining the methylation levels 
from all the sites in the element. Repeat elements were 
highly methylated, approaching 100  %. No effect of age 
or sex was observed (two-way ANOVA), and methylation 
levels approached 100 % in the repeat elements.
Total hmC levels
hmC is more abundant in the brain [29, 51] as com-
pared to other tissues. Previous studies have described 
increased total hmC levels with aging (Additional file 1: 
Table S3). Total hmC levels were measured by ELISA 
in young and old, male, and female Set 2 mice (n =  6/
group). No differences were observed with age or sex 
(two-way ANOVA) (Fig. 7).
Whole‑genome oxidative bisulfite sequencing
Arguably the most accurate and specific method to 
quantify mC and hmC levels that also include genomic 
location and context (CG vs CH) information is whole-
genome sequencing. Two methods for base-specific 
quantitation of mC and hmC have been recently 
described: TET-assisted bisulfite sequencing (TAB-Seq) 
[52] and oxidative bisulfite sequencing (oxBS-Seq) [53, 
54]. We applied the oxBS-Seq approach to specifically 
quantifying mC and hmC genome wide in young and old 
male and female mouse hippocampus. The primary limi-
tation of whole-genome sequencing of mC and hmC is 
that to quantify every base with strand specificity enor-
mous amounts of sequencing data are required [at least 
166  Gb per sample (3.2  Gb genome  ×  2 strands  ×  2 
libraries × 10× coverage/~70 % of reads passing QC and 
alignment)]. This is far beyond the scope of this study. 
However, to take advantage of oxBS-Seq we sequenced 
genomes at a lower coverage and summed methylation or 
hydroxymethylation counts for each sample from aligned 
reads by chromosome and by genomic element [CpG 
Islands (CGIs), or promoters]. This approach provides 
hundreds of thousands to hundreds of millions of indi-
vidual base counts for each sample, and quantitation can 
be split into different contexts (CG or CH) (Additional 
file 1: Table S8).
Young and old, male and female hippocampus samples 
(n = 3/group) were analyzed by oxBS-Seq. Female sam-
ples were aligned to the mouse genome without the Y 
chromosome, while males were aligned to the complete 
mouse genome. Methylation counts were separated by 
CG and CH contexts and by chromosome. No age or sex 
differences (Two-way ANOVA) in mCG-specific meth-
ylation levels were observed for autosomes, but higher 
X chromosome methylation was evident in females as 
compared to males (factor of sex p  =  0.0008) (Fig.  8a) 
and between young females and males (SNK, p = 0.001) 
and between old females and old males (SNK, p = 0.008). 
There was no difference in male Y chromosome mCG 
with aging.
Methylation of the CH context (Fig.  8b) was much 
lower than CGs, as has been previously reported [45]. 
It should be noted that the number of CH sites in the 
genome is ten times that of CG sites, and while most 
CH sites are unmethylated, individual sites can be quite 
highly methylated (e.g., [55]), thus explaining the low 
mean values. No sex or age differences were evident in 
autosomes or the X and Y chromosomes.
Summing the counts within chromosomes does not 
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Female Male
Fig. 7 Global hmC levels: ELISA. Total/global levels of hmC were 
analyzed by ELISA (young and old, females and males Set 2) with the 
provided synthetic hydroxymethylation standards. No age or sex dif-
ferences in total hmC were observed
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different methylation levels and patterns. Methylation 
counts were averaged across all annotated CGIs and all 
promoter regions of annotated RefSeq genes for each 
mouse in 100-bp bins for promoters and 200-bp bins 
for CGIs (Fig.  8c, d). mCG levels reached nadirs over 
the islands and at the TSS with higher levels upstream 
and downstream. This pattern of methylation, low over 
islands, and near the TSS has been previously observed 
with traditional bisulfite sequencing of brain tissues, but 
the absolute values here are lower as the quantitation pre-
sented here is mC specific [41]. mCG levels were lower 
in old males than young males across CGI shores and 
shelves (Fig. 8e). There were no significant age or sex dif-
ferences in CGI shores, shelves, or the island itself (two-
way ANOVA, BHMTC for multiple regions). In promoter 
regions, mCG methylation was lower in old males as 
compared to old females in the 1-kb upstream (two-way 
ANOVA factor of age, p = 0.005, SNK old female versus 
old male p = 0.004) and downstream of the TSS (two-way 
ANOVA factor of age, p = 0.003, SNK old female versus 
old male p = 0.003) (Fig. 8f ). These differences were of a 
small magnitude (<2 % absolute difference).
For hmC quantitation in CG contexts, there were no 
significant differences in autosomal hmCG (Fig.  9a). 
On the X chromosome, hmCG methylation was greater 
in males than in females as well as in old males as com-
pared to young males (two-way ANOVA factor of sex 
p  =  0.0002, SNK young female versus young male 
p = 0.007, SNK old female versus old male p = 0.0005). 
There was no difference in hmCG levels with aging on 
the Y chromosome, and methylation levels were much 
lower than other chromosomes. In the CH context, hmC 
levels were extremely low (<0.1 %), consistent with previ-
ous reports of other CNS regions [56] (Fig. 9b), and no 
differences with sex or age were observed. In CGIs and 
promoter regions, hmCG levels were lowest in the island 
itself and around the TSS before reaching near genome-
wide levels (~15  %) upstream and downstream (Fig.  9c, 
d). In CGIs (Fig. 9e), a higher level of hmCG in shelves 
(Two-way ANOVA, BHMTC, factor of age p  =  0.003, 
SNK female young versus old p = 0.036, SNK male young 
versus old p  =  0.01) and shores (two-way ANOVA, 
BHMTC, factor of age p = 0.004, SNK male young ver-
sus old p = 0.007) upstream of the island with aging were 
observed. A similar pattern in the downstream shelves 
(Two-way ANOVA, BHMTC, factor of age p  =  0.004, 
SNK female young versus old p = 0.038, SNK male young 
versus old p  =  0.013) and shores (two-way ANOVA, 
BHMTC, factor of age p = 0.002, SNK female young ver-
sus old p = 0.022, SNK male young versus old p = 0.006) 
was evident. In promoter regions (Fig. 9f ), no sex or age 
effects passed multiple testing corrections. Similarly to 
mCG the differences in hmCG with aging were of a small 
absolute magnitude (<5 %).
Discussion
Through the application of multiple analytical 
approaches to independent cohorts of young (3  M), 
adult (12 M) and old (24 M) male and female mice and 
using the hippocampus as a sentinel brain structure, we 
demonstrate that: (1) expression of DNMTs and TETs is 
not regulated by aging or by sex; (2) DNMT3a2 expres-
sion in the mature hippocampus is minimal and does 
not change with aging; and (3) total genomic methyla-
tion and hydroxymethylation levels do not change with 
age. Rather, specific levels of mC and hmC differ with 
aging and by sex, depending on the chromosomal, pro-
moter and CGI context. From a technical standpoint, 
these experiments demonstrate the need for appropriate 
quantitation controls, such as species-specific methyla-
tion standards, spike-in conversion controls, assessment 
of assay quantitative accuracy, differential quantitation of 
mC and hmC, and separation of CG and CH dinucleotide 
contexts.
DNMT and TET regulation
Analysis of DNMT and TET expression with aging in 
males and females across independent sets of animals 
found no consistent changes in gene expression. Previ-
ous reports of hippocampal DNMT and TET expression 
with aging have shown a mixture of results, and the find-
ings here provide clear evidence that these genes are not 
regulated with aging in either males or females. Addi-
tionally, examination of the public human gene expres-
sion data finds no evidence for changes in expression 
with aging. Many of the previous reports of differential 
expression have been of very small magnitude changes or 
have used immunohistochemical methods not well suited 
(See figure on next page.) 
Fig. 8 Global mC levels: whole-genome sequencing. Specific levels of mC were analyzed by oxidative bisulfite sequencing. a mC levels in the CG 
context for autosomes, X, and Y chromosomes were analyzed in young and old females and males. b In the CH context, mC levels were much lower 
as compared to CG. c mCG levels in CpG islands, shores, and shelves for all annotated CGIs per sample were combined and plotted in 200 bp bins. 
d All annotated promoter regions (±2 kb of TSS, 100-bp bins) methylation was lowest at the TSS with higher levels further upstream and down-
stream. e Statistical comparisons of islands as well as upstream and downstream shores and shelves revealed slightly lower levels in Old males. f For 
promoter regions, mCG levels in 1-kb bins upstream and downstream of the TSS were compared. Two-way ANOVA, SNK post hoc **p < 0.01
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for quantitation [8, 21]. Using multiple animal cohorts of 
male and female mice, our findings should aid in resolv-
ing this ambiguity in how the expression of these genes 
changes with age. The possibility remains that differential 
expression may occur with aging in very specific subpop-
ulations of cells or in other CNS regions which could be 
investigated in future studies. The equivalent expression 
of DNMTs and TETs in males and females provides evi-
dence that the sex differences in total mC and hmC levels 
for the X chromosome, and the different levels of auto-
somes and sex chromosomes, are the result of altered tar-
geting and not expression of these regulating enzymes.
Expression of DNMT3a2 (the short isoform of 
DNMT3a), previously reported as a regulator of cognitive 
aging [8], was not initially detectable in any of the young, 
adult, or old animals. DNMT3a2 preferentially localizes 
to euchromatin, while DNMT3a1 is predominantly found 
in heterochromatin [38], suggesting differential expres-
sion with aging of DNMT3a2 could have important 
genome regulatory effects. Using a state-of-the-art digital 
PCR approach, we found that DNMT3a2 expression rap-
idly declines from E11 to PN1 and is present in amounts 
marginally above background in the mature hippocam-
pus. Even at these low levels of expression, no differences 
were observed with age in either males or females. The 
likely explanation for the difference in our findings from 
previous results is that the previous report of 20–25  % 
suppression of DNMT3a2 (and DNMT3a1) with aging 
assumed 100  % reaction efficiency, greater than the 
75–76 % observed here, likely leading to an overestima-
tion of the differences between groups. Even though our 
findings contradict the concept of declining hippocampal 
DNMT3a2 expression with aging, the improved learning 
and memory performance achieved by genetic induction 
of DNMT3a2 levels [8, 57] may be valid. However, a more 
accurate interpretation would be that of re-introduction 
of a developmentally silenced gene rather than restora-
tion of an age-related decline in expression which leads 
to improved learning and memory.
Genomic hypomethylation
The genomic hypomethylation hypothesis was first 
developed 40  years ago [58], and while many stud-
ies have examined methylation levels in blood samples 
from humans, this hypothesis has been extended to the 
CNS, being reported as generally accepted [15, 18–20]. 
However, for the brain and in this case the hippocam-
pus in particular, the primary data from controlled lab-
oratory animal models are divergent (Additional file  1: 
Table S1) and a hypomethylated genome with aging 
could also be expected to lead to a widespread increase 
in gene expression, which is not observed (e.g., [59]). 
Using antibody-based ELISAs of total genomic mC and 
bisulfite pyrosequencing of repeat elements, we find no 
hypomethylation with age. By the definitive approach of 
whole-genome oxBS-Seq, we also demonstrate that there 
is no evidence of genomic hypomethylation with age in 
the mouse hippocampus. Stated alternatively, the average 
levels of mC across the entire genome do not change with 
aging in either males or females.
Most of the previous reports of changes in total 
genomic methylation with aging have used antibody 
detection methods (ELISA and IHC). The technical limi-
tations of these antibody-based methods are as follows: 
(1) they do not differentiate based on cytosine context 
(CG vs CH); (2) they are usually performed with methyla-
tion standards that have higher CG densities than found 
in mammalian genomes; and (3) the likelihood that anti-
body binding is biased against CG dense regions [60] 
reduces the reliability of these antibody-based measure-
ments. Inclusion of appropriate methylation standards 
improved quantitation, but ultimately sequencing-based 
approaches are needed to quantify mC accurately and 
provide a genomic context to these data. The technical 
reasons for why previous reports have observed signifi-
cant hypomethylation with aging are not as clear. This 
study specifically examined the hippocampus and analy-
sis of other brain regions, tissues, and specific cell types 
with quantitatively rigorous techniques such as oxBS-Seq 
is needed. Future cell type-specific analyses of sorted or 
laser-captured selected cells are needed to provide cel-
lular specificity to the understanding of changes in DNA 
methylation with aging. The agreement of our hippocam-
pal data in terms of total genomic levels and patterns at 
specific genomic elements with the few datasets available 
from other brain regions supports the hypothesis that 
no hypomethylation with aging will be observed in other 
brain regions.
(See figure on previous page.) 
Fig. 9 Global hmC levels: whole-genome sequencing. a Specific levels of hmC, derived from oxidative bisulfite sequencing, were analyzed for 
autosomes and sex chromosomes. b hmC in the CH context was quantified in autosomes and sex chromosomes. c hmCG levels in CpG islands, 
shores, and shelves for all annotated CGIs per sample were combined and plotted in 200-bp bins. d In promoter regions (±2 kb of TSS, 100-bp bins), 
hydroxymethylation was lowest around the TSS with higher levels further upstream and downstream. e Statistical comparisons of islands as well as 
upstream and downstream shores and shelves revealed higher hmCG levels in shores and shelves with aging. f In promoter regions, hmCG levels 
were greater in 1- to 2-kb bins upstream in females with aging and 1- to 2-kb downstream of the TSS in males with aging. Two-way ANOVA, SNK 
post hoc *p < 0.05, **p < 0.01
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Our findings do provide evidence of some subtle dif-
ferences in methylation by sex in sex chromosomes, as 
would be expected. Additionally, small age-related dif-
ferences were observed in promoter regions when spe-
cifically analyzed. With the genome-wide approach used 
here, determination of the individual differentially meth-
ylated promoters (or CGIs) is not possible. However, in-
depth oxBS analysis with base- and strand-specific mCG/
mCH quantitation at appropriate sequencing depths may 
reveal subsets of CGIs, promoters, and other genomic 
regions (e.g., enhancers) that are differentially methylated 
with aging, sex, or both. In addition, the data presented 
here provide novel insights into methylation patterns in 
the brain. The specific hippocampal quantitation of mC 
confirms total mCG levels of ~50  % and mCH levels of 
<1  %. These values are lower than observed in bisulfite 
sequencing studies that combine mC and hmC, but are 
in agreement if the sum of our mC and hmC data is 
taken together [41]. Across CGIs and promoter regions, 
a U-shaped pattern was observed that correlates with 
previous findings from other brain regions [56]. The 
highly different mC levels within relatively small genomic 
regions of a few hundred base pairs further empha-
size the need for base-specific quantitation. Alternative 
approaches to mC quantitation such as fragmentation 
and immunoprecipitation, which quantify over a region, 
and microarray approaches, which use a single CG site 
for a region, cannot resolve these patterns.
Genomic hydroxymethylation
Sequencing data on hmC in the brain are quite limited 
since advanced techniques have only recently been devel-
oped and optimized [53, 54]. Utilizing the ability of oxBS-
Seq to specifically quantify hmC, a total level of ~15  % 
hmCG was observed, which is in agreement with recent 
reports on human cortex and cerebellum [56, 61]. Sex 
chromosome hmCG levels are lower than autosomes. 
Intriguingly, the levels of hmCH are at an extremely 
low level, <0.01 %, similar to a previous report using an 
alternate sequencing method (TAB-Seq) [45]. While the 
ratio of mCG/hmCG is ~3, the ratio for mCH/hmCH is 
~10, which may be a result of the higher affinity of TET 
enzymes for the CG over CH context [62].
Existing data on hippocampal hmC differences with 
aging or by sex are limited. Although we find that total 
hmC levels do not change with age, the higher level of 
hmCG in males than in females for the X chromosome 
has not been previously reported. Female samples did 
have more sequencing counts as compared to males as 
would be expected from having twice the X chromo-
somes, but this sex difference warrants further investiga-
tion. The age-related differences in hmCG in CGI shores 
and shelves were the inverse of those observed for mCG. 
This shift in males from mCG to hmCG in CGI shores 
and shelves with aging is a novel finding. Again, while 
these changes are relatively small in magnitude, more 
in-depth sequencing studies are needed to quantify dif-
ferential methylation and hydroxymethylation at higher 
resolution with aging.
Technical notes
We are unaware of other studies that have applied mul-
tiple different analytical techniques to examine mC and 
hmC dynamics with aging. The comparison of the results 
from these different approaches provides valuable insight 
into the technical performance of assays used in epig-
enomic studies. For ELISA-based quantitation, use of 
methylation standards with highly different CG density 
than the genome examined impairs quantitative accu-
racy and the absolute values differed from those observed 
by the more accurate sequencing approaches. Use of 
species-specific standards in the ELISA returned more 
accurate quantitation and avoided issues such as those 
in the literature where the sum of mC and hmC levels 
exceeds 100 % [24]. Nonetheless, the inability of ELISAs 
to differentiate between CG and CH contexts and quan-
titative limitations makes these widely reported measure-
ments of limited value. It is not clear why some reports 
describe large differences in total genomic methylation 
with aging, but by the more accurate sequencing meth-
ods, which include conversion rate controls, presented 
here there is no evidence of changes in total methylation 
or hydroxymethylation levels. Pyrosequencing of repeat 
elements of the genome is often described as a surro-
gate for whole-genome levels [48, 49], though this was 
not found to be the case in our study. mC levels in LINE 
and SINE repeat elements approached 100 % rather than 
the ~50 % observed genome wide with oxidative bisulfite 
sequencing. The inclusion of synthetic spike-in controls 
in bisulfite and oxidation reactions provides a firmer 
quantitative foundation for sequencing studies. Previ-
ous approaches of using methylation in the CH context 
as the conversion control can overestimate failed conver-
sion due to the natural occurrence of mCH. Finally, as 
demonstrated in the DNMT3a2 experiments, insufficient 
characterization of assays, e.g., determining reaction effi-
ciencies, can apparently cause spurious findings of differ-
ences in gene expression.
Conclusion
While the hypothesis of down-regulated DNMT and 
TET expression with aging and subsequent decreases in 
total levels of mC and/or hmC is seductive, the findings 
presented here provide extensive evidence that this is not 
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the case in the murine hippocampus. Rather, these find-
ings and others demonstrate the need to examine abso-
lute methylation and hydroxymethylation levels across 
the genome in a base- and strand-specific manner with 
aging. In addition, our data point to the need to measure 
DNA modifications in both males and females, i.e., one 
cannot assume that age-related changes in DNA modifi-
cations in one sex will be mirrored in the other sex. Dis-
covery of specific genomic loci with age-related changes 
in DNA modifications will enable studies of both the 
functional effects of an altered epigenome and the regu-




All animal experiments were performed according to 
protocols approved by the Penn State University and Uni-
versity of Oklahoma Health Sciences Center (OUHSC) 
Institutional Animal Care and Use Committees. Male 
and female C57BL/6 mice ages 3, 12, and 24 months were 
purchased from the National Institute on Aging Colony 
at Charles River Laboratories (Wilmington, MA). Set 1 
mice were housed in the specific pathogen-free Penn-
sylvania State University College of Medicine Hershey 
Center for Applied Research facility in ventilated HEPA-
filtered cages with ad libitum access to sterile chow (Har-
lan 2918 irradiated diet, Indianapolis, IN) and water. Set 
2 mice were housed in the specific pathogen-free Rodent 
Barrier Facility at OUHSC in filter-top cages with ad libi-
tum access to sterile chow (5053 Pico Lab; Purina Mills, 
St. Louis, MO) and water. In both facilities, all animals 
are free of helicobacter and parvovirus. For both sets 
of animals, following a one-week acclimation period on 
entering the respective facility, male mice were eutha-
nized by decapitation. Female mice were euthanized dur-
ing diestrus after estrous cycle staging.
Estrous cycle staging was performed by daily vaginal 
lavage to control for cycling differences. Lavages were 
conducted as described previously [55] and using well-
established methods [63]. Briefly, sterile filtered water 
was expelled and aspirated approximately 4–5 times 
into the vaginal canal until enough cells were obtained 
for cytological analysis. Water from the vaginal wash 
was then placed onto a glass slide, allowed to dry, and 
then stained using 0.1 % crystal violet. The estrous cycle 
consists of three major phases: proestrus (high estro-
gen), estrus (low estrogen), and diestrus (low estrogen). 
Proestrus is defined by having a predominance of round, 
nucleated epithelial cells, estrus by cornified squamous 
epithelial cells, and diestrus by leukocytes with few epi-
thelial cells present [63].
Hippocampal cultures
Mixed co-cultures of neurons (both cortical and hip-
pocampal) were isolated from C57BL/6 mice on embry-
onic day 18–20 (E18–20) in accordance with the 
approved Institutional Animal Care and Use Committees 
guidelines at OUHSC. Neurons were isolated as previ-
ously described [64]. In brief, following enzymatic diges-
tion and trituration, hippocampal cells were resuspended 
in growth media [DMEM containing 2 % NuSerum, 10 % 
fetal bovine serum, penicillin (10 units/ml), streptomycin 
(10 μg/ml), and l-glutamine (29.2 μg/ml)] at a density of 
300,000 cells/plate and seeded on 50  μg/ml poly-d-ly-
sine-coated 6-cm dishes. Cells were fed every 3–4 days, 
with half of the conditioned media being replaced with 
fresh growth media. Neurons were treated with 30  µM 
fluorodeoxyuridine (FDU) on day 3 to reduce astrocyte 
proliferation. On day 9, neurons in culture were treated 
with either 50 µM of bicuculline (Sigma, St. Louis, MO) 
in vehicle (DMSO) or 50  mM of KCl for 4  h. Controls 
were either left untreated or treated with vehicle. Follow-
ing treatment, neurons were rinsed with 0.1 M PBS pH 
7.4 and harvested for further analysis.
Quantitative PCR
RNA preparation was performed according to stand-
ard methods [AllPrep DNA/RNA Mini (Qiagen, Valen-
cia, CA)] as described previously [65]. RNA quality was 
assessed by RNA 6000 Nano LabChip with an Agilent 
2100 Expert Bioanalyzer (Agilent, Palo Alto, CA). Only 
samples with RNA integrity numbers greater than 7 were 
used in subsequent studies. RNA concentration was 
assessed by relative fluorescence using the RiboGreen 
assay (Invitrogen, Carlsbad, CA, USA).
cDNA was reverse-transcribed with random primers 
[ABI high-capacity cDNA reverse transcription kit (Life 
Technologies, Foster City, CA)] as previously described 
[66]. qPCR was performed with gene-specific prim-
ers and hydrolysis fluorogenic probes (Additional file  1: 
Table S5) (TaqMan, Life Technologies, and PrimeTime, 
IDT, Coralville, IA) as previously described [59]. Rela-
tive gene expression was calculated with ExpressionSuite 
version 1.0.3 software using the 2−ΔΔCt analysis method 
with β-actin as an endogenous control. β-actin was deter-
mined as a stable endogenous control through digital 
PCR across ages and sexes examined.
qPCR efficiency for each of the two DNMT3a2 
assays was determined as follows: cDNA dilution 
series (1000, 750, 500, 250, 125 ng) was generated from 
mouse E13 brain RNA. qPCR was performed as above, 
the Ct was graphed against log (DNA copy #), and 
the slope of the line was used to determine efficiency 
[E = −1 + 10(slope/−1)] [67].
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Digital PCR
Digital PCR (dPCR) was carried out by mixing 3.33  μl 
diluted template DNA (50 ng/μl, diluted 1:10 for E11 and 
E18, 1:2 for PN1 and undiluted for 3  M hippocampus); 
concentrations of DNA are described below and var-
ied by experiment with 16.5  μl QuantStudio 3D master 
mix, 3.33  μl 20× gene expression assay, and 9  μl water 
[32.16 μl (enough for two chips with excess)] (Life Tech-
nologies). Reactions were loaded onto QuantStudio 
3D digital PCR chips (20,000 wells per chip) using the 
QuantStudio 3D chip loader according to manufacturer’s 
instructions (Life Technologies). Chips were then sealed 
and cycled on a GeneAmp PCR system 9700 with a flat-
block attachment using the following conditions: Stage 
1—96 °C for 10 min, Stage 2—60 °C for 2 min and then 
98  °C for 30 s (repeat Stage 2 39 times), Stage 3—60  °C 
for 2  min and an infinite 10  °C hold. Chips were then 
read in the QuantStudio 3D chip reader (Life Technolo-
gies) to obtain raw fluorescent values per well. Quality 
check of the chips and counting of positive and negative 
wells in order to determine copies/microliter were car-
ried out on the QuantStudio 3D AnalysisSuite cloud soft-
ware (LifeTechnologies) using the absolute quantification 
module and then calculated to copies per μg of input 
RNA including incorporating dilutions stated above.
Immunoblotting
Tissue (hippocampus or cortex as noted) or cell culture 
lysates were solubilized in a detergent-based protein lysis 
buffer containing protease and phosphatase inhibitors 
(100 mM NaCl, 20 mM HEPES, 1 mM EDTA, 1 mM dith-
iothreitol, 1.0  % Tween 20, 1  mM Na3VO4, 1 complete 
mini EDTA-free protease inhibitor cocktail tablet (Roche 
Applied Science, Indianapolis, IN, USA) for every 10 ml 
lysis buffer) using a bead mill (Retsch TissueLyzer II; Qia-
gen). Homogenates were incubated at 4  °C with gentle 
rocking for 15  min, and insoluble protein was removed 
by centrifugation (10,000g, 15  min, 4  °C). The soluble 
protein-containing supernatant was collected, and pro-
tein concentrations were determined by bicinchoninic 
acid (BCA) quantitation (Thermo Fisher, Waltham MA).
The DNMT3a1 protein standard was generated by 
transient transfection of a pCMV6 vector containing the 
full-length human DNMT3a1 (NM_175629, OriGene, 
Rockville MD) with a C-terminal Myc-DDK (FLAG) tag 
into HEK293T cells and cultured for 48  h. Cells were 
lysed with RIPA buffer [25 mM Tris–HCl pH7.6, 150 mM 
NaCl, 1 % NP-40, 1 mM EDTA, 1× proteinase inhibitor 
cocktail mix (Sigma), 1  mM PMSF and 1  mM Na3VO4] 
and protein concentrations determined by BCA assay. 
Protein was then affinity purified by anti-DDK (FLAG) 
antibody. Affinity-purified DNMT3a1-FLAG was loaded 
at 0.1 μg for testing detection by primary antibodies.
Immunoblotting was performed according to stand-
ard methods [68, 69]. Protein samples were adjusted 
to a concentration of 3  μg/μl in protein lysis buffer and 
LDS sample buffer (Invitrogen, Carlsbad, CA). Fifteen μg 
of each prepared protein sample (except where noted) 
was denatured at 95  °C and reduced with DTT prior to 
sodium dodecyl sulfate-polyacrylamide gel electropho-
resis separation using criterion Tris–HCl precast 4–20 % 
acrylamide gradient gels (Bio-Rad, Hercules, CA, USA). 
An independent gel containing parallel aliquots of study 
samples was stained with deep purple total protein stain 
(GE Healthcare, Piscataway, NJ, USA) and quantitated 
by whole-lane digital densitometry (ImageQuant TL; 
Molecular Dynamics, Sunnyvale, CA, USA) to ensure 
equal protein content between samples as reported previ-
ously [68, 69]. For immunoblotting, proteins were trans-
ferred to polyvinylidene difluoride membranes (HyBond; 
GE Healthcare), blocked with 3  % BSA in PBS contain-
ing 1 % Tween-20, and incubated with primary antibod-
ies (Additional file 1: Table S6). Membranes were washed 
with PBS containing 1 % Tween-20, incubated with spe-
cies-appropriate secondary antibodies (Additional file 1: 
Table S6), and visualized with enhanced chemilumines-
cence substrate (GE Healthcare). Immunoreactive bands 
were imaged on film, digitized at a resolution of 800 d.p.i. 
with a transmissive scanner, and quantitated using auto-
mated digital densitometry software with rolling ball 
background subtraction (ImageQuant TL).
mC and hmC ELISA
Total levels of mC and hmC, regardless of genomic 
context, were analyzed by colorimetric ELISAs (Zymo 
Research, D5326 and D5426, respectively, Irvine, CA). 
Isolated genomic DNA (as described above) concentra-
tions were quantified by fluorescent assay (PicoGreen, 
Invitrogen) and all samples brought to the same concen-
tration. ELISAs were performed in technical triplicates 
with 100  ng per well for mC and 200  ng for hmC after 
determining these amounts were within the linear range 
of the assays. For the first mC ELISA, Set 1 samples, the 
supplied 897-bp in vitro generated methylation standards 
were used. 5  % of these sequences are cytosines in CG 
contexts, much higher than the ~1 % found in the mouse 
genome. For the second performance of the mC ELISA, 
using Set 2 samples, the methylation standard curve was 
generated with a serial mixture of mouse gDNA meth-
ylation standards (low ~5 % and high ~95 %, EpigenDx, 
Hopkinton, MA) to provide an accurate quantitation of 
methylation levels. Methylation standards were quanti-
fied by pyrosequencing and whole-genome sequencing 
as previously described [70]. It should be noted, however, 
that these mouse methylation standards are only meth-
ylated at CG motifs as the standards are generated by 
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in vitro treatment with M. SssI. The hmC ELISA standard 
curve was generated with the same synthetic standard as 
above, but with every cytosine in a CG context hydroxy-
methylated. No whole mouse genome hmC standards 
currently exist. In both cases, the antibody used in these 
ELISAs is specific to mC or hmC but cannot determine 
genomic locations or differentiate between CG and CH 
contexts.
Repeat element pyrosequencing
Methylation levels of repetitive elements were examined 
as a surrogate of genome-wide methylation changes. Five 
hundred  ng of gDNA (n  =  4/group) was bisulfite con-
verted (EZ DNA methylation-lighting, Zymo Research) 
and PCR amplified using primers for LINE-1 and B1 ele-
ments (EpigenDx). Following PCR amplification, pyrose-
quencing was conducted by EpigenDx and methylation 
was analyzed in these selected regions.
Oxidative bisulfite sequencing
Oxidative bisulfite sequencing (oxBS) was performed 
according to previously described methods [53, 54]. For 
oxidative bisulfite sequencing, two parallel sets of librar-
ies are constructed. The first uses traditional bisulfite 
conversion in which all Cs are converted through deami-
nation to Us and mC and hmC are protected from con-
version. In the second, DNA is oxidized with KRuO4 and 
all hmC are converted to 5fC. Subsequent bisulfite treat-
ment converts all Cs and 5fCs to Us. In this manner, a 
specific mC signal is identified and hmC levels are deter-
mined by subtracting oxBS signal from BS signal.
Specifically, 400 ng of gDNA (n = 3/group) was sheared 
to an average size of 800 bp by sonication (E220, Cova-
ris). DNA sizing was confirmed by capillary electropho-
resis chip (Bioanalyzer DNA 1000, Agilent). One 200 ng 
aliquot of each sample was oxidized and then bisulfite 
converted, while the other 200 ng was only bisulfite con-
verted (TrueMethyl, Cambridge Epigenetix, Cambridge, 
UK). Libraries were then constructed from the converted 
DNAs by end finishing and addition of Illumina adapt-
ers and indexes. Libraries were sized by capillary chip 
(high-sensitivity DNA chip, Agilent) and quantified by 
qPCR (Kappa Biosystems, Wilmington, MA). Librar-
ies were loaded at 12 ρM and then sequenced by 150 bp 
paired-end reads on an Illumina NextSeq. Conversion 
rates for oxidation and bisulfite treatment for each sam-
ple preparation were determined from spike-in controls 
with unmodified Cs, as well as specific bases with mC, 
and hmC. Conversion rates were >99 % for bisulfite and 
>97 % for oxidation with minimal variance between sam-
ples (Additional file 1: Figure S1). The full complement of 
sequencing data has been posted to the Sequencing Read 
Archive (data to be publically released on publication).
Paired-end reads were filtered for low quality using a 
Q-score ≥25 and a maximum of 1 ambiguous nucleo-
tide. Adapter trimming was performed in CLC Genom-
ics Workbench 8.5.1 using Illumina universal adapter 
sequences. An additional 3 bp was trimmed off the 3′ and 
5′ end of each of the paired-end reads. All computations 
were done in Unix and R using custom scripts unless 
specified otherwise. Reads were mapped to the reference 
mouse genome (GRCm38/mm10) using Bismark Bisulfite 
Mapper version 0.14.4 [71]. Female samples were 
mapped to all autosomes and chrX. Male samples were 
mapped to autosomes, chrX, and a chrY not containing 
homologous X sequences in order to maximize unique 
mapping. Methylation calls were made for both BS and 
oxBS sequences using bismark methylation extractor. The 
output from oxBS yields the methylation value for mC, 
while the output from BS yields the methylation value for 
mC and hmC. Average hmC levels were calculated as the 
difference between these two readouts (BS-oxBS).
Using a tiling approach, average of non-overlapping 
100-bp windows for promoters and 200-bp windows for 
annotated CGI (16,009, http://hgdownload.soe.ucsc.edu/
goldenPath/mm10/database/), shores, and shelves was 
computed in order to identify mC and hmC levels dif-
ferences in CG-rich locations. Promoters were defined 
as the TSS ±  2  kb flanking region of all protein-coding 
genes included in the RefSeq database obtained from 
the UCSC website. Shores and shelf were defined as 
±4 kb from the CGI [72] and were calculated based on 
the position relative to annotated CGIs. This sequencing 
approach allows differentiation of mC from hmC meth-
ylation, and levels can be separated by chromosome and 
between CG and CH contexts.
Human microarray meta‑analysis
All human microarray experimental data were obtained 
from NCBI’s GEO database of publicly available micro-
array experiments and collapsed to genes by max mean 
using the probe–gene mappings provided by the AILUN 
database [73]. The SQLite GEOmetadb database contain-
ing descriptions of the experiments was downloaded, and 
the age and tissue of each sample was extracted using text 
mining. The following random-effects linear model was 
fit to the dataset using R’s lme4 package, where expres-
sion indicates the per-gene Z-score of log-expression 
across all samples:
Tissue of origin, experiment, and microarray platform are 
controlled for using random effects in this model. Results 
(p value, t statistic, and linear model coefficient) for the 
age coefficient of this formula are presented.
Expression ∼ Age+ (1|TissueID)
+ (1|ExperimentID) + (1|PlatformID)
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Statistics
Statistical analyses were performed with SigmaStat 3.5 
(SyStat Software, San Jose, CA) unless otherwise stated. 
Gene expression (qPCR and dPCR) data were analyzed 
by two-way ANOVA with the factors of sex and age. For 
factors and interactions passing the critical threshold 
(α  <  0.05), appropriate Student–Newman–Keuls (SNK) 
pairwise post hoc testing with α  <  0.05 was performed. 
ELISA and pyrosequencing data were analyzed by the 
same two-way ANOVA approach. Whole-genome mC 
and hmC data were analyzed by two-way ANOVA on 
counts from the specific genomic region or element as 
described.
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